SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide

The most recent release (May 14 2026) is a BioMedWire editorial feature highlighting SureNano’s subsidiary GlucaPharm and its GEP‑44 triple‑agonist peptide for obesity and type 2 diabetes. It reiterates the pipeline’s potential for improved efficacy, tolerability, and non‑injectable delivery. No new clinical data, regulatory milestones, or material corporate updates are disclosed; the piece is promotional in nature.

This editorial is a paid or arranged media mention that simply repackages information already disclosed in the May 11‑13 releases (preclinical data, IND‑enabling studies, delivery platform ambitions). It contains no genuinely new information that would alter the company’s fundamental outlook. Consequently, the impact on the investment thesis is negligible – it is routine positive noise that may temporarily boost visibility but does not change the risk‑reward profile. The market has not priced any material shift on this news, and the stock price ($0.24) remains well below the $0.35 warrant exercise level set in the recent financing.

SureNano Science Ltd. is a Canadian‑listed (CSE: SURE, OTCQB: SURNF) company that originally focused on a proprietary surfactant technology. In February 2026 it acquired GlucaPharm Inc., pivoting to a biotech model centered on metabolic disease. Its flagship asset is GEP‑44, a patented triple‑agonist peptide (GLP‑1 + PYY Y1/Y2 receptors) exclusively licensed from Syracuse University. Preclinical data published in May 2026 shows ~15% weight loss (vs ~9% for liraglutide), ~39% food‑intake reduction, and a notable absence of nausea/GI side effects. The company is advancing GEP‑44 through FDA IND‑enabling toxicology/pharmacology studies with LabCorp and plans to seek a Clinical Trial Notification in Australia for Phase I. It also aims to develop oral, sublingual, and intranasal formulations to improve patient adherence. Additionally, SureNano is exploring ibogaine‑related IP for addiction and PTSD, but no binding agreements have been signed.